Approximately 94%.


Attention: Don't Sleep On (NBY), A Tiny Float NYSE American Past Champ With 5 Potential Breakout Catalysts

June 26th

SCF Readers,

Approximately 94%.

That's what happened when I delivered this past champ to your screens to close out 2022.

All this NYSE American profile did was run $1.00+ in the span of a handful of days.

Solid move, but now with it on the climb during the month of June, it could very well be nearing breakout territory again.

Right now, I'm bringing this breakout idea back to your attention in a fully-detailed report.

Below, you'll discover exactly why this profile requires a top spot on your watch-list.

With a low float consisting of fewer than 3Mn shares, volatility could be off the hook.

How about a massive analyst target suggesting as much as 1,400+% potential upside from Friday's close?

At $12.00, the target provides a glimpse into the upside potential of this NYSE American profile from current trading levels.

Plus, this company has recently fulfilled a significant order totaling $1Mn through a key Chinese partnership.

This prominent importer, and marketer of branded pharmaceuticals and medical devices in China, demonstrates this company's growing presence in the international market.

Based on these potential catalysts and more, this NYSE American profile requires immediate attention once again:

*NovaBay Pharmaceuticals, Inc. (NBY)*

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products.

NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid.

And based on multiple potential catalysts, NBY requires top spot on your watch-list now. Check them out:

No. 1 - Explosive Volatility Potential From Tiny Float

No. 2 - Analyst Targets Could Suggest As Much As 1,400% Potential Upside

No. 3 - Company's Products Appear On Flagship Shopping Channel "QVC"

No. 4 - Chinese Order Demonstrates Growing Presence In International Markets

No. 5 - The Wound Care Market Could Be A "Larger Part" Of NBY's 2023 Business

But more on those in a second...

Corporate Overview - The Inner-Workings Of NBY

Established Brands in Three Verticals

  • Avenova - #1 doctor-recommended antimicrobial lid & lash spray in the U.S. dry eye market
  • DERMAdoctor - more than 30 highly effective, problem-solving dermatological products
  • PhaseOne and NeutroPhase cutting-edge wound care technology

Complementary Product Lines

  • Innovative, proprietary OTC products address underserved customer needs
  • Similar customer demographic across all brands
  • Scientifically developed and clinically proven – not cosmetic

Cohesive Mission

  • Sales & marketing DTC expertise to create a strong, fast-growing company
  • Expanding distribution and international reach
  • Creating science-based, problem-solving, accessible solutions for improved well-being

Avenova - Science for sore eyes.

  • No. 1 Doctor-Recommended Antimicrobial Lid & Lash Spray
  • Pioneering use of hypochlorous acid (HOCl) – a substance naturally produced by the body – for antimicrobial lid & lash spray
  • Kills a broad spectrum of bacteria and helps relieve chronic eye conditions like dry eye, blepharitis, styes, contact lens discomfort and inflammation
  • 510(k) FDA-cleared formulation is the only known stable, truly pure HOCI commercial solution
  • Manufactured and lab tested in the U.S. and clinically proven to be the most effective lid & lash solution available without a prescription
  • 80-100 times more potent than Clorox bleach yet completely nontoxic

Avenova Opp's for Growth


DERMAdoctor: Established Brand in Growing Skincare Market

Established Brand

  • Founded in 1998 by Drs. Audrey and Jeff Kunin
  • Over 30 high-quality skincare products

Scientifically Formulated Proprietary Products

  • Created by board-certified dermatologist
  • Focus on alleviating and healing common skin conditions: dry skin, blemishes, keratosis pilaris and aging
  • Effective, hypoallergenic, and problem-solving

Significant Global Growth Opp.

  • Cosmetic skincare products estimated to reach $185Bn by 2027
  • The skincare segment is growing faster than any other part of the beauty industry

New Partners Enhance Marketing in China

Major growth opp. with new partners

  • Tmall store (Amazon equivalent) upgraded with Duomai
  • UNQ to provide additional influencer marketing

Growing market for functional skincare products

  • China market expected to exceed $100Bn by 2024
  • Accounting for >22% of the total Chinese skincare market


Cutting Edge Wound Care Technology

  • The safe and effective HOCl solution for managing viruses, bacteria and fungi
  • Leverages NovaBay proprietary HOCl technology
  • Rx product for routine and tough cases
  • Distributed through partners (PhaseOne Health (U.S.) & Pioneer Pharma (China))

Grab Source And Key Details Here: Company Presentation.


And as mentioned above, NBY has several potential catalysts that could help provide a breakout spark. Check these out:

No. 1 NBY Potential Catalyst - Explosive Volatility Potential From Tiny Float

According to the Yahoo Finance website, NBY has a tiny low float.

The website reports this profile to have approximately 2.55Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more positive company news in 2023 provide a near term spark?


No. 2 NBY Potential Catalyst - Analyst Targets Could Suggest As Much As 1,400% Potential Upside

Edward Woo, an analyst at Ascendiant Capital Markets, has tagged NBY with a $12.00 price target.

From this past Friday's close, that provides NBY with an incredible upside potential of 1,400%.

Here's some key highlights from his report:

  • Avenova unit growth again: Avenova sales were $2.1Mn. Avenova had continued year-over-year growth in online Avenova Spray unit sales.
  • DERMAdoctor contribution: DERMAdoctor sales were $1.0Mn, and reflects the 4 rd full quarter of sales since the acquisition closed in November 2021 (in Q4 2021). In September 2021, NovaBay announced the acquisition of privately held DERMAdoctor for ~$12Mn (in cash).
  • DERMAdoctor: DERMAdoctor produces and sells more than 30 products under lines that include Ain’t Misbehavin’, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge. Its products are designed to address acne, aging skin, dark spots, dry skin, eczema, and many other skin conditions. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, Costco, digital beauty retailers such as SkinStore and Amazon, as well as its own website. DERMAdoctor also has a large and growing network of international distributors and retailers. DERMAdoctor’s management has joined the NovaBay management team.
  • Management long term positive: NovaBay is making good progress to market its Avenova product to the 41 million Americans ($600Mn market opp.) who suffer from blepharitis and related eye symptoms. In addition, the acquisition of DERMAdoctor allows strong growth and synergy opp's in the global market for cosmetic skincare products. NovaBay plans to launch a broad range of complementary eye and skin care products. The company also plans to leverage operational synergies and sales/distribution relationships.
  • We remain positive: Despite st-ock and fi-nan-cial results volatility, we believe that NovaBay is a compelling ... story. The company’s focus in 2023 is to drive Avenova and DERMAdoctor sales to consumers by focusing on current products as well as new product launches.


No. 3 NBY Potential Catalyst - Company's Products Appear On Flagship Shopping Channel "QVC"

NovaBay Pharmaceuticals Announces DERMAdoctor’s KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC at a Special Price

Chief Product Officer Dr. Audrey Kunin to showcase KP Duty combo with supercharged exfoliators and moisturizers to help rapidly lift away dry, rough bumps and reveal healthier looking skin

EMERYVILLE, Calif., June 12, 2023--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Dr. Audrey Kunin will appear on QVC®’s Girls Night In with Courtney & Jane on Tuesday, June 13, 2023 at 10:00 p.m. Eastern time to showcase DERMAdoctor®’s system for dry, rough, bumpy skin. The two-piece Ultra Duo set of KP Duty Scrub and KP Duty Lotion, both in the 8-ounce size, will be available at QVC for a special price of $56.50.

"Our KP Duty Ultra Duo is specially formulated as a two-step system to help temporarily exfoliate, smooth, and hydrate dry, rough, and bumpy skin on the body, together with moisturizers to help hydrate for softer, more supple and smoother looking skin," said Dr. Audrey Kunin, a board-certified dermatologist. "Like all DERMAdoctor products, KP Duty Scrub and KP Duty Lotion are dermatologist tested to be non-irritating and ideal for year-round use."

KP Duty Body Scrub is formulated with a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids for a dual action physical and chemical exfoliation of the skin that temporarily removes the dead surface skin cells, and a hydrating botanical blend of Evening Primrose, Black Currant Seed Oil, Borage Seed Oil, and White Tea Leaf Extract.

KP Duty Lotion is formulated with a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids to temporarily exfoliate the skin to help alleviate skin roughness and improve the appearance of skin texture and smoothness, along with ceramides, botanicals and the humectant Urea to help temporarily hydrate and moisturize the skin.

Dr. Audrey Kunin is an author, clinician, educator, television personality and recognized trailblazer in the skincare industry. DERMAdoctor delivers on the promise that skin therapy can be simple and easy. All DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns.

Read the full article here.


No. 4 NBY Potential Catalyst - Chinese Order Demonstrates Growing Presence In International Markets

NovaBay Pharmaceuticals Fulfills $1Mn Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings

EMERYVILLE, Calif., May 01, 2023--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1Mn order for NovaBay’s NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in the second quarter of 2023.

"NeutroPhase is the safest, purest and most powerful hypochlorous acid wound cleanser on the market yet is gentle, non-irritating and non-sensitizing to skin and new tissue," said Justin Hall, CEO of NovaBay Pharmaceuticals. "Importantly, NeutroPhase differentiates itself in the marketplace because it does not contain the toxic chemicals found in many other wound care products. We proudly manufacture NeutroPhase in the U.S. in large batch quantities through a proprietary process."

"The efficacy of NeutroPhase is unparalleled in the wound care market. We are proud of our long-term partnership with NovaBay and are delighted to make this high-quality product available to our healthcare customers in China," said Paul Li, Chairman of China Pioneer.


Read the full article here.


No. 5 NBY Potential Catalyst - The Wound Care Market Could Be A "Larger Part" Of NBY's 2023 Business

PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market

PhaseOne is uniquely formulated with NovaBay Pharmaceuticals’ unique and proprietary hypochlorous acid

NASHVILLE, Tenn. & EMERYVILLE, Calif., January 17, 2023--(BUSINESS WIRE)--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid.

"We expect wound care to be a larger part of our business in 2023 and we are excited to partner with PhaseOne Health to grow our sales in the coming year," said Justin Hall, CEO of NovaBay Pharmaceuticals.

Kris Perkins, Managing Director of PhaseOne Health, further explained, "We are building on triple-digit percentage growth over the last few years by aligning with key opinion leaders and advisors to expand our commercial programs in 2023. Combining our past commercial success with recent results in new clinical applications positions us well to pursue synergistic business and protocol development with other companies and providers to address large market opportunities not only in wound care but in other surgical applications as well."


PhaseOne differentiates itself in the wound care market by utilizing NovaBay’s unique formulation of HOCI. Through its proprietary manufacturing process and amber glass bottle, NovaBay ensures the safest, purest, most powerful HOCl wound cleanser on the market. Its effectiveness is independently documented in the study Comparative Antimicrobial Activity of Commercial Wound Care Solutions on Bacterial and Fungal Biofilms (Harriott, PhD et al) published in the peer-reviewed journal Annals of Plastic Surgery.


Read the full article here.


NBY Recap - The Top Potential Catalysts For This NYSE American Past Champ

No. 1 - Explosive Volatility Potential From Tiny Float

No. 2 - Analyst Targets Could Suggest As Much As 1,400% Potential Upside

No. 3 - Company's Products Appear On Flagship Shopping Channel "QVC"

No. 4 - Chinese Order Demonstrates Growing Presence In International Markets

No. 5 - The Wound Care Market Could Be A "Larger Part" Of NBY's 2023 Business


Coverage is officially reinitiated on NBY. When time allows, do this:


Get NBY on your radar now.


Axel Adams

Editor, SCF

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

SmallCapFirm "SCF" (smallcapfirm . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a license d finan.cial advise r. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: An owner of SWN Media LLC owns and operates fierceinvestor . com (“FI”), owns and operates stockwirenews . com ("SWN"), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 6/25/23 and ending on 6/27/23 to publicly disseminate information about (NBY) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred and one cent USD via bank wire transfer. We own zero shares of (NBY). We previously profiled (NBY) in 2022 and were not compensated for that profile. This is our first time being compensated for (NBY). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 06/20/2023 and ending on 07/28/2023 to publicly disseminate information about (NBY:US) via digital communications. We have been paid two hundred thousand dollars USD. We own zero shares of (NBY:US).